ALK wild-type

Most patients preferred atezolizumab SC regardless of baseline characteristics, mean injection duration, and cumulative number of SC injections. The trend for a stronger preference was higher among patients who preferred SC than those who preferred IV. Our findings suggest that the proportion of preference for atezolizumab SC over IV is highest in patients aged > 74 years, and that administrator's experience could be an important factor influencing patient preference.

P3, N=594, Active, not recruiting, AstraZeneca | Trial completion date: Oct 2025 --> Oct 2026

P2, N=69, Not yet recruiting, The Second Affiliated Hospital of Nanjing Medical University; The Second Affiliated Hospital of Nanjing Medical University

P2, N=29, Active, not recruiting, Georgetown University | Recruiting --> Active, not recruiting | N=42 --> 29

Using a nationwide, deidentified database, we selected adults with unresectable stage IIIB/IIIC/IV NSCLC and ECOG performance status of 0-1, excluding those in a clinical trial, who initiated first-line pembrolizumab plus platinum/pemetrexed from 1 June 2017 through 30 September 2021 (EGFR/ALK-wild-type nonsquamous NSCLC) or pembrolizumab plus carboplatin/(nab)-paclitaxel from 1 November 2018 through 30 September 2020 (squamous NSCLC). At 5 years, OS rates were 21.6% and 18.2%, respectively, with 5-year OS rates by tumor PD-L1 < 1%/1-49%/≥50% expression of 15.8%/19.8%/32.6% in nonsquamous and 15.2%/14.1%/32.6% in squamous cohorts. First-line pembrolizumab plus chemotherapy demonstrates long-term effectiveness for nonsquamous and squamous advanced/metastatic NSCLC, with 5-year OS rates in real-world settings that are consistent across PD-L1 expression strata with 5-year outcomes from the pivotal clinical trials.

P2, N=69, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting

Surgically resected ALK-rearranged NSCLC involves an increased risk of recurrence and reduced DFS, notably within the first 3 years, accompanied by higher rates of systemic and brain metastases. These findings underscore the importance of tailored postoperative surveillance strategies and suggest the potential role of perioperative ALK-tyrosine kinase inhibitors.

P2, N=39, Active, not recruiting, AstraZeneca | Trial completion date: Jul 2025 --> Jan 2027

P2, N=60, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025

P2, N=142, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting

Patients with persistent mediastinal lymph node metastases (ypN2) should be discussed for adjuvant radiotherapy on a risk-adapted individual basis.A broad consensus was reached at the expert conference on the topics discussed in the context of the new perioperative therapy concepts. These can therefore serve as practice-oriented support for the members of the DGT.

P3, N=1027, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting